Redmile Group

Were Hedge Funds Right About Buying PRA Health Sciences Inc (PRAH)? | Yahoo News | 12/3/2019

… PRAH), which was worth $118.2 million at the end of the third quarter. On the second spot was AQR Capital Management which amassed $110.4 million worth of shares. Point72 Asset Management, Millennium Management, and Redmile Group were also very fond of the stock, becoming one of the largest hedge fund holders of the company. In terms of the portfolio weights assigned to each position Endurant Capital Management allocated the biggest …

Metropolitan Life Insurance Co NY Has $3.44 Million Position in Centene Corp (NYSE:CNC) | 12/2/2019

… its holdings in Centene by 958.2% in the 3rd quarter. Man Group plc now owns 819,037 shares of the company’s stock valued at $35,431,000 after acquiring an additional 741,637 shares in the last quarter. Redmile Group LLC raised its holdings in Centene by 17.3% in the 3rd quarter. Redmile Group LLC now owns 810,498 shares of the company’s stock valued at $35,062,000 after acquiring an additional 119,628 shares in the …

Follow Redmile Group:    

Redmile Group LLC Acquires 32,000 Shares of Wright Medical Group NV (NASDAQ:WMGI) | 11/30/2019

… filing with the Securities and Exchange Commission. The firm owned 2,404,157 shares of the medical device company’s stock after buying an additional 32,000 shares during the period. Wright Medical Group accounts for 1.7% of Redmile Group LLC’s investment portfolio, making the stock its 20th biggest position. Redmile Group LLC owned approximately 1.89% of Wright Medical Group worth $49,598,000 as of its most recent SEC filing. Other institutional investors and hedge …

Redmile Group LLC Sells 4,400 Shares of Akero Therapeutics (NASDAQ:AKRO) - WKRB News | 11/30/2019

… quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,164,402 shares of the company’s stock after selling 4,400 shares during the period. Redmile Group LLC’s holdings in Akero Therapeutics were worth $26,490,000 as of its most recent SEC filing. Several other institutional investors have also bought and sold shares of the business. Cormorant Asset Management LP bought a …

Redmile Group LLC Decreases Stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) | 11/30/2019

986.43 Million in Sales Expected for Paychex, Inc. (NASDAQ:PAYX) This Quarter Redmile Group LLC Decreases Stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Redmile Group LLC Decreases Stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) - Filed Under - by Jeff Wilder Tweet Redmile Group LLC lowered its holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 0.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and …

Redmile Group LLC Lowers Position in Akero Therapeutics (NASDAQ:AKRO) | 11/30/2019

… the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,164,402 shares of the company’s stock after selling 4,400 shares during the period. Redmile Group LLC owned approximately 4.08% of Akero Therapeutics worth $26,490,000 at the end of the most recent reporting period. Several other large investors have also added to or reduced their stakes in AKRO. Griffin Asset …

Redmile Group LLC Sells 4,330 Shares of Stoke Therapeutics (NASDAQ:STOK) | 11/30/2019

… third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,017,478 shares of the company’s stock after selling 4,330 shares during the period. Redmile Group LLC owned about 3.11% of Stoke Therapeutics worth $21,866,000 at the end of the most recent quarter. A number of other institutional investors have also added to or reduced their stakes in the business …

Redmile Group LLC Has $55.35 Million Stock Holdings in Nevro Corp (NYSE:NVRO) | 11/30/2019

… most recent disclosure with the Securities & Exchange Commission. The firm owned 643,864 shares of the medical equipment provider’s stock after purchasing an additional 640,464 shares during the period. Nevro makes up about 1.9% of Redmile Group LLC’s holdings, making the stock its 19th biggest position. Redmile Group LLC owned 2.08% of Nevro worth $55,353,000 as of its most recent SEC filing. Several other institutional investors also recently made changes to …

Redmile Group LLC Purchases 119,628 Shares of Centene Corp (NYSE:CNC) | 11/30/2019

… quarter, according to its most recent disclosure with the SEC. The firm owned 810,498 shares of the company’s stock after purchasing an additional 119,628 shares during the period. Centene accounts for about 1.2% of Redmile Group LLC’s investment portfolio, making the stock its 27th biggest holding. Redmile Group LLC owned approximately 0.20% of Centene worth $35,062,000 as of its most recent filing with the SEC. A number of other large …

Redmile Group LLC Takes Position in Penumbra Inc (NYSE:PEN) | 11/30/2019

… company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 297,972 shares of the company’s stock, valued at approximately $40,074,000. Penumbra accounts for about 1.3% of Redmile Group LLC’s holdings, making the stock its 23rd biggest position. Redmile Group LLC owned about 0.85% of Penumbra at the end of the most recent reporting period. Several other institutional investors have also recently made …

Redmile Group LLC Reduces Stock Holdings in Tandem Diabetes Care Inc (NASDAQ:TNDM) | 11/30/2019

… 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,160,401 shares of the medical device company’s stock after selling 5,631 shares during the quarter. Tandem Diabetes Care accounts for approximately 2.3% of Redmile Group LLC’s holdings, making the stock its 13th biggest holding. Redmile Group LLC owned 1.96% of Tandem Diabetes Care worth $68,440,000 at the end of the most recent quarter. Other hedge funds have also recently …

Redmile Group LLC Raises Position in Syros Pharmaceuticals Inc (NASDAQ:SYRS) | 11/30/2019

… its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,888,752 shares of the company’s stock after purchasing an additional 268,376 shares during the period. Syros Pharmaceuticals accounts for 1.4% of Redmile Group LLC’s investment portfolio, making the stock its 22nd biggest holding. Redmile Group LLC owned approximately 9.16% of Syros Pharmaceuticals worth $40,365,000 as of its most recent filing with the Securities & Exchange Commission. Several other …

Scholar Rock Holding Corp (NASDAQ:SRRK) Shares Sold by Redmile Group LLC | 11/30/2019

986.43 Million in Sales Expected for Paychex, Inc. (NASDAQ:PAYX) This Quarter Scholar Rock Holding Corp (NASDAQ:SRRK) Shares Sold by Redmile Group LLC Scholar Rock Holding Corp (NASDAQ:SRRK) Shares Sold by Redmile Group LLC - Filed Under - by Stacy Sanders Tweet Redmile Group LLC decreased its holdings in Scholar Rock Holding Corp (NASDAQ:SRRK) by 2.2% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 2,857,389 shares of the …

Redmile Group LLC Increases Position in Horizon Therapeutics PLC (NASDAQ:HZNP) | 11/30/2019

… Horizon Therapeutics PLC (NASDAQ:HZNP) by 28.9% in the third quarter, Holdings Channel.com reports. The institutional investor owned 14,700 shares of the biopharmaceutical company’s stock after acquiring an additional 3,300 shares during the quarter. Redmile Group LLC’s holdings in Horizon Therapeutics were worth $400,000 as of its most recent filing with the SEC. Other large investors have also made changes to their positions in the company. New York State Teachers …

Chimerix Inc (NASDAQ:CMRX) Holdings Lowered by Redmile Group LLC - TheOlympiaReport | 11/30/2019

… CMRX) by 9.1% during the third its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,235,795 shares of the biopharmaceutical company’s stock after selling 322,593 shares during the quarter. Redmile Group LLC owned about 0.05% of Chimerix worth $7,604,000 as of its most recent filing with the Securities and Exchange Commission. Several other hedge funds also recently added to or reduced their stakes in CMRX …

Redmile Group LLC Acquires 640,464 Shares of Nevro Corp (NYSE:NVRO) - WKRB News | 11/30/2019

… 18,837.2% during the third quarter, Holdings Channel reports. The fund owned 643,864 shares of the medical equipment provider’s stock after purchasing an additional 640,464 shares during the period. Nevro makes up about 1.9% of Redmile Group LLC’s portfolio, making the stock its 19th biggest position. Redmile Group LLC’s holdings in Nevro were worth $55,353,000 as of its most recent SEC filing. A number of other hedge funds and other institutional …

Redmile Group LLC Reduces Holdings in Xencor Inc (NASDAQ:XNCR) | 11/29/2019

… during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 879,627 shares of the biopharmaceutical company’s stock after selling 733,171 shares during the period. Redmile Group LLC owned 1.55% of Xencor worth $29,670,000 at the end of the most recent reporting period. Other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc …

Tandem Diabetes Care Inc (NASDAQ:TNDM) Shares Sold by Redmile Group LLC - TheOlympiaReport | 11/29/2019

… by 0.5% in the third quarter, HoldingsChannel reports. The firm owned 1,160,401 shares of the medical device company’s stock after selling 5,631 shares during the quarter. Tandem Diabetes Care makes up approximately 2.3% of Redmile Group LLC’s holdings, making the stock its 13th largest holding. Redmile Group LLC’s holdings in Tandem Diabetes Care were worth $68,440,000 at the end of the most recent reporting period. A number of other large …

Redmile Group LLC Boosts Stock Holdings in AnaptysBio Inc (NASDAQ:ANAB) | 11/29/2019

… quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 612,558 shares of the biotechnology company’s stock after purchasing an additional 2,900 shares during the period. Redmile Group LLC owned approximately 2.26% of AnaptysBio worth $21,433,000 at the end of the most recent reporting period. Several other hedge funds have also modified their holdings of the company. Squarepoint Ops LLC raised its …

Redmile Group LLC Purchases New Position in Inspire Medical Systems (NYSE:INSP) - WKRB News | 11/29/2019

Redmile Group LLC purchased a new stake in Inspire Medical Systems (NYSE:INSP) during the third quarter, according to its most recent filing with the SEC. The firm purchased 3,910 shares of the company’s stock, valued at approximately $239,000. Several other large investors have also recently made changes to their positions in the stock. Strs Ohio raised its position in shares of Inspire Medical Systems by 8.7% in the 2nd …

Food and Drug Administration

Global Myelodysplastic Syndrome Treatment Market to Surpass US$ 4,994.7 million by 2027 - Coherent Market Insights | Business Wire | 11/25/2019

… mg/vial, a generic version of Celgene’s vidaza injection, 100 mg/vial, in the U.S. Mylan N.V. received the U.S. Food and Drug Administration (FDA) approval for its abbreviated new drug route of administration (ANDA … million series C financing round led by healthcare investment organization, Redmile Group, along with participation of new investor Rock Springs Capital and current existing investors. This investment will enable the company to initiate Phase 3 …

Global Myelodysplastic Syndrome Treatment Market to Surpass US$ 4,994.7 million by 2027 - Coherent Market Insights | Malvern Daily Record | 11/25/2019

… mg/vial, a generic version of Celgene’s vidaza injection, 100 mg/vial, in the U.S. Mylan N.V. received the U.S. Food and Drug Administration (FDA) approval for its abbreviated new drug route of administration (ANDA … million series C financing round led by healthcare investment organization, Redmile Group, along with participation of new investor Rock Springs Capital and current existing investors. This investment will enable the company to initiate Phase 3 …

Medical Documentation

Remote Medical Documentation Company Augmedix Closes $19 Million In Funding | 11/6/2019

Remote medical documentation company Augmedix announced that it raised $19 million in Series B funding from Redmile, McKesson, DCM, and Wanxiang Healthcare. Augmedix — a remote medical documentation company — announced recently that it raised $19 million in Series B funding. This round of funding includes investments from Redmile Group, McKesson Ventures, DCM Ventures, Wanxiang Healthcare Investments, and several others. With this round of funding, Augmedix plans to use the funding to …

Health tech funding snapshot—Google joins $50M round in Viz.ai, Augmedix raises $19 million, and more | FierceHealthcare | 11/1/2019

… medical documentation: Tech-enabled remote documentation company Augmedix uses natural-language-processing technology and remote medical documentation experts to help reduce the burden of medical documentation for physicians. The San Francisco-based company landed $19 million in Series B funding that included investments from Redmile Group, McKesson Ventures, DCM Ventures, Wanxiang Healthcare Investments, and others. Augmedix provides clinicians with hardware, smartphones or Google Glass, to stream the clinic visit to …

Biotech

20 Things You Didn’t Know about BioNTech SE | 11/2/2019

BioNTech SE is a biotechnology company that recently went public. Of all the new companies listed on the market in this industry, BioNTech has yielded among the most promising candidates in the massive pipeline, which … Series A funding in January 4, 2018, led by the Redmile Group. In July of 2019, a round of series B funding led by Fidelity and the Redmile Group raised an additional $225,600,000, and teh …

Here is What Hedge Funds Think About Krystal Biotech, Inc. (KRYS) | Yahoo News | 10/30/2019

… we analyze the activity of those elite funds in these small-cap stocks. In the following paragraphs, we analyze Krystal Biotech, Inc. (NASDAQ: a href=”https://www.insidermonkey.com” rel=”nofollow noopener” target=”_blank” KRYS /a ) from … stake in Krystal Biotech, Inc. (NASDAQ:KRYS) was held by Redmile Group , which reported holding $43.5 million worth of stock at the end of March. It was followed by Baker Bros. Advisors with a $41.7 …

Medical Research

-$0.04 Earnings Per Share Expected for Heska Corp (NASDAQ:HSKA) This Quarter - TheOlympiaReport | 10/18/2019

… firms that follow Heska. Get Heska alerts: Heska (NASDAQ:HSKA) last released its earnings results on Tuesday, August 6th. The medical research company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.07 … after acquiring an additional 10,521 shares in the last quarter. Redmile Group LLC lifted its position in shares of Heska by 14.3% in the first quarter. Redmile Group LLC now owns 226,013 shares of the …

Heska Corp (NASDAQ:HSKA) Expected to Post Quarterly Sales of $30.44 Million - Ticker Report | 10/15/2019

… that follow Heska. Get Heska alerts: Heska (NASDAQ:HSKA) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, topping the Thomson … after purchasing an additional 5,019 shares in the last quarter. Redmile Group LLC lifted its holdings in shares of Heska by 14.3% in the first quarter. Redmile Group LLC now owns 226,013 shares of the …

Medicare

After shutdown, telemedicine company Call9’s founder plans a comeback | Modern Healthcare | 7/25/2019

Medicare. Its $24 million Series B round in 2017 attracted Redmile Group, a San Francisco–based investment firm that had previously focused on biotech companies. ArchCare, which runs the Mary Manning Walsh Nursing Home on the Upper East Side, was one of Call9’s early clients. Scott LaRue, ArchCare’s CEO, said he was impressed with Peck and Call9’s results. But the nursing home was able to get its patients …

Startup Call9 shutting down operations for telehealth services to nursing homes | FierceHealthcare | 6/26/2019

Medicare and for the long-term health of startups. But we also know that fee for service can give you more revenue compensation in the short-term, and start-ups often feel that pressure to focus their efforts there,” Peck said, according to CNBC. Investors in Call9 included Redmile Group, Index Ventures, Refactor Capital and Y Combinator …

Gene Therapy

Audentes Therapeutics: Encouraging Progress In XLMTM, Pipeline Continues To Evolve - Audentes Therapeutics, Inc. (NASDAQ:BOLD) | Seeking Alpha | 5/28/2019

… showing a young patient who, prior to treatment, could not even sit up (was on ventilator). After being treated with gene therapy candidate AT132, the child was shown playing with a toy (and essentially enjoying … Baker Brothers has been adding to its stake as have Redmile Group and BB Biotech. Great Point Partners and Orbimed Advisors also own decent-sized positions. A history of some insider selling is not encouraging …

Biotech builder ElevateBio reveals its first portfolio company: AlloVir | FierceBiotech | 5/22/2019

ElevateBio launched just last week with $150 million to build cell and gene therapy companies. Now, it’s unveiling its first portfolio company: AlloVir, a biotech working on off-the-shelf T-cell therapies against several … in series B financing from a slate of investors including Redmile Group, EcoR1 Capital and Samsara BioCapital, all of which backed ElevateBio’s series A. Fidelity Management and Research Company, Gilead Sciences, F2 Ventures, Invus and …

AnaptysBio

AnaptysBio (NASDAQ:ANAB) Sees Strong Trading Volume - Dakota Financial News | 12/3/2019

Shares of AnaptysBio Inc (NASDAQ:ANAB) saw unusually-high trading volume on Monday . Approximately 1,091,837 shares were traded during mid-day trading, an increase of 151% from the previous session’s volume of 435,734 shares.The stock … 285,000 after purchasing an additional 1,209 shares during the period. Redmile Group LLC increased its stake in shares of AnaptysBio by 0.5% during the third quarter. Redmile Group LLC now owns 612,558 shares of the …

Redmile Group LLC Boosts Stock Holdings in AnaptysBio Inc (NASDAQ:ANAB) | 11/29/2019

Redmile Group LLC Boosts Stock Holdings in AnaptysBio Inc (NASDAQ:ANAB) Posted by Kim Johansen on Nov 29th, 2019 // Comments off Redmile Group LLC boosted its stake in shares of AnaptysBio Inc (NASDAQ:ANAB) by 0.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 612,558 shares of the biotechnology company’s stock after purchasing an additional 2,900 shares …

PRA Health Sciences

Were Hedge Funds Right About Buying PRA Health Sciences Inc (PRAH)? | Yahoo News | 12/3/2019

… believe it isn’t a waste of time to check out hedge fund sentiment before you invest in a stock like ;PRA Health Sciences Inc (NASDAQ: a href=”http://www.insidermonkey.com/insider-trading/company/pra%20health%20sciences … million worth of shares. Point72 Asset Management, Millennium Management, and Redmile Group were also very fond of the stock, becoming one of the largest hedge fund holders of the company. In terms of the portfolio …

PRA Health Sciences Inc (NASDAQ:PRAH) Shares Sold by Redmile Group LLC | 6/17/2019

Redmile Group LLC lessened its position in PRA Health Sciences Inc (NASDAQ:PRAH) by 10.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 174,000 shares of the medical research company’s stock after selling 20,800 shares during the period. Redmile Group LLC owned about 0.27% of PRA Health Sciences worth $19,190,000 as of its most recent SEC …

Wright Medical

$259.35 Million in Sales Expected for Wright Medical Group NV (NASDAQ:WMGI) This Quarter | Daily Political | 12/2/2019

Wall Street analysts expect that Wright Medical Group NV (NASDAQ:WMGI) will report sales of $259.35 million for the current fiscal quarter, according to Zacks Investment Research . Fifteen analysts have issued estimates for Wright Medical … after acquiring an additional 141,799 shares during the period. Finally, Redmile Group LLC lifted its holdings in Wright Medical Group by 1.3% in the third quarter. Redmile Group LLC now owns 2,404,157 shares of the …

Redmile Group LLC Acquires 32,000 Shares of Wright Medical Group NV (NASDAQ:WMGI) | 11/30/2019

Redmile Group LLC increased its holdings in Wright Medical Group NV (NASDAQ:WMGI) by 1.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,404,157 shares of the medical device company’s stock after buying an additional 32,000 shares during the period. Wright Medical Group accounts for 1.7% of Redmile Group LLC’s investment portfolio, making the stock its …

Celgene

Top Funds’ Activity in Q3 2019 | 11/30/2019

… Buys/Increases: Peloton Interactive Inc (NASDAQ: PTON ) Ally Financial Inc (NYSE: ALLY ) BP plc (NYSE: BP ) Citigroup Inc (NYSE: C ) Celgene Corporation (NASDAQ: CELG ) Notable Q3 Sells/Reductions: PowerShares QQQ Trust, Series 1 (NASDAQ: QQQ … Investors 14) Consonance Capital Management 15) Camber Capital Management 16) Redmile Group 17) RTW Investments 18) Bridger Capital Management 19) Boxer Capital 20) Bridgeway Capital Management 21) Cohen & Steers 22) Cardinal Capital Management 23) Munder …

Global Myelodysplastic Syndrome Treatment Market to Surpass US$ 4,994.7 million by 2027 - Coherent Market Insights | Business Wire | 11/25/2019

… period. For instance, in June 2016, Mylan N.V. launched its azacitidine for injection, 100 mg/vial, a generic version of Celgene’s vidaza injection, 100 mg/vial, in the U.S. Mylan N.V. received the U.S. Food … million series C financing round led by healthcare investment organization, Redmile Group, along with participation of new investor Rock Springs Capital and current existing investors. This investment will enable the company to initiate Phase 3 …

Augmedix

Remote Medical Documentation Company Augmedix Closes $19 Million In Funding | 11/6/2019

Remote medical documentation company Augmedix announced that it raised $19 million in Series B funding from Redmile, McKesson, DCM, and Wanxiang Healthcare. Augmedix — a remote medical documentation company — announced recently that it raised $19 million in Series B funding. This round of funding includes investments from Redmile Group, McKesson Ventures, DCM Ventures, Wanxiang Healthcare Investments, and several others. With this round of funding, Augmedix plans to use the funding to …

Health tech funding snapshot—Google joins $50M round in Viz.ai, Augmedix raises $19 million, and more | FierceHealthcare | 11/1/2019

Augmedix uses natural-language-processing technology and remote medical documentation experts to help reduce the burden of medical documentation for physicians. The San Francisco-based company landed $19 million in Series B funding that included investments from Redmile Group, McKesson Ventures, DCM Ventures, Wanxiang Healthcare Investments, and others. Augmedix provides clinicians with hardware, smartphones or Google Glass, to stream the clinic visit to a cloud-based platform. Fifteen national health …

Epizyme

17,653 Shares in Epizyme Inc (NASDAQ:EPZM) Purchased by Man Group plc | 11/2/2019

Man Group plc purchased a new position in shares of Epizyme Inc (NASDAQ:EPZM) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 17,653 shares of the … 80,831,000 after purchasing an additional 1,552,216 shares during the period. Redmile Group LLC raised its stake in Epizyme by 15.9% during the first quarter. Redmile Group LLC now owns 7,694,020 shares of the biopharmaceutical company’s …

Brokerages Anticipate Epizyme Inc (NASDAQ:EPZM) to Announce -$0.54 EPS | 10/15/2019

Wall Street analysts expect that Epizyme Inc (NASDAQ:EPZM) will announce ($0.54) earnings per share (EPS) for the current quarter, according to Zacks Investment Research . Four analysts have provided estimates for Epizyme’s earnings, with the … investors have recently bought and sold shares of the company. Redmile Group LLC boosted its position in shares of Epizyme by 15.9% during the 1st quarter. Redmile Group LLC now owns 7,694,020 shares of the …

Genentech

20 Things You Didn’t Know about BioNTech SE | 11/2/2019

… Family Office, and other funders, followed by a round of Series A funding in January 4, 2018, led by the Redmile Group. In July of 2019, a round of series B funding led by Fidelity … for targeting patient neoantigens for the individualized treatment of cancer. Genentech Inc is a firm under the Roche umbrella. The companies entered into a deal worth $310,000,000 for research and collaboration on a product license …

IPO Update: BioNTech Proposes U.S. IPO Terms - BioNTech (Pending:BNTX) | Seeking Alpha | 9/30/2019

Genentech ( ROG ) in a Phase 1a/1b trial for the treatment of patients with late stage advanced cancers, including patients that failed multiple lines of prior treatment. Below is the current status of the company’s drug development pipeline: Source: Company registration statement Investors in BioNTech have included Fidelity Management and Research, Platinum Asset Management, MiraeAsset Asset Management, Jebsen Capital, Invus, BVCF, Athena Capital, Redmile Group, Sanofi ( SNY ), and MIG among …

Teladoc

Were Hedge Funds Right About Warming Up To Teladoc Health Inc (TDOC)? | Yahoo News | 11/1/2019

… hedge funds’ purchases. We know better. That’s why we scrutinize hedge fund sentiment before we invest in a stock like ;Teladoc Health Inc (NYSE: a href=”http://www.insidermonkey.com/insider-trading/company/teladoc%20inc/1477449/” rel … its 13F portfolio. Coming in second is Jeremy Green of Redmile Group , with a $30.7 million position; 0.9% of its 13F portfolio is allocated to the company. Some other members of the smart money with …

Redmile Group LLC Buys 244,300 Shares of Teladoc Health Inc (NYSE:TDOC) | 7/10/2019

Redmile Group LLC Buys 244,300 Shares of Teladoc Health Inc (NYSE:TDOC) Posted by Charles Blunt on Jul 9th, 2019 Redmile Group LLC grew its position in Teladoc Health Inc (NYSE:TDOC) by 124.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 439,900 shares of the health services provider’s stock after purchasing an additional 244,300 shares during the …

McKesson

Health tech funding snapshot—Google joins $50M round in Viz.ai, Augmedix raises $19 million, and more | FierceHealthcare | 11/1/2019

… Redmile Group, McKesson Ventures, DCM Ventures, Wanxiang Healthcare Investments, and others. Augmedix provides clinicians with hardware, smartphones or Google Glass, to stream the clinic visit to a cloud-based platform. Fifteen national health systems, including Sutter Health, CommonSpirit Health, and US Oncology, currently partner with Augmedix. Clinical trial technology: Healthcare technology company SignalPath raised $18 million Series B funding led by existing investors with a total raise of capital to …

Augmedix announces $19 million in Series B funding | 10/26/2019

Augmedix announces $19 million in Series B funding Emily Boerger Oct 25, 2019 Share this: Click to share on Tumblr (Opens in new window) On Thursday, Augmedix announced it has received $19 million in Series B funding. The new funding includes investments from McKesson Ventures, DCM ventures, Redmile Group, Wanxiang Healthcare Investments, and others. Augmedix turns clinician-patient conversations into medical documentation in real time. They do this by providing …

Pfizer

Nuvation Bio Pulls In $275M | 10/29/2019

… Redmile Group, Surveyor Capital (a Citadel Company) and other institutional investors.The Series A financing will enable Nuvation Bio to expand its development activities and advance a number of its oncology programs.Nuvation Bio was founded by industry veteran David Hung, M.D., who previously founded and served as President and Chief Executive Officer of Medivation, Inc., which was subsequently sold to Pfizer, Inc. for $14.3 billion in 2016.”My vision for Nuvation …

Oncology Start-Up Nuvation Bio Closes $275 Million Series A Financing Led by Omega Funds | BioSpace | 10/28/2019

… Redmile Group, Surveyor Capital (a Citadel Company) and other institutional investors. The Series A financing will enable Nuvation Bio to expand its development activities and advance a number of its oncology programs. Nuvation Bio was founded by industry veteran David Hung , M.D., who previously founded and served as President and Chief Executive Officer of Medivation, Inc., which was subsequently sold to Pfizer, Inc. for $14.3 billion in 2016. “My vision …

BlackRock Inc.

Wave Life Sciences Ltd (NASDAQ:WVE) Receives Consensus Recommendation of “Buy” from Brokerages | 12/4/2019

Redmile Group LLC increased its stake in Wave Life Sciences by 16.8% in the 3rd quarter. Redmile Group LLC now owns 3,177,760 shares of the company’s stock worth $65,239,000 after buying an additional 458,053 shares during the period. BlackRock Inc. increased its stake in Wave Life Sciences by 6.7% in the 2nd quarter. BlackRock Inc. now owns 1,811,996 shares of the company’s stock worth $47,275,000 after buying an additional 113,292 …

$259.35 Million in Sales Expected for Wright Medical Group NV (NASDAQ:WMGI) This Quarter | Daily Political | 12/2/2019

… shares of the medical device company’s stock valued at $339,666,000 after acquiring an additional 81,975 shares during the last quarter. BlackRock Inc. lifted its holdings in Wright Medical Group by 4.8% in the second quarter … after acquiring an additional 141,799 shares during the period. Finally, Redmile Group LLC lifted its holdings in Wright Medical Group by 1.3% in the third quarter. Redmile Group LLC now owns 2,404,157 shares of the …

Rock Springs Capital

Top Funds’ Activity in Q3 2019 | 11/30/2019

… 59) Tourbillon Capital Partners 60) Impala Asset Management 61) Valinor Management 62) Marshall Wace 63) Light Street Capital Management 64) Rock Springs Capital Management 65) Rubric Capital Management 66) Whale Rock Capital 67) York Capital … Investors 14) Consonance Capital Management 15) Camber Capital Management 16) Redmile Group 17) RTW Investments 18) Bridger Capital Management 19) Boxer Capital 20) Bridgeway Capital Management 21) Cohen & Steers 22) Cardinal Capital Management 23) Munder …

Global Myelodysplastic Syndrome Treatment Market to Surpass US$ 4,994.7 million by 2027 - Coherent Market Insights | Business Wire | 11/25/2019

… Redmile Group, along with participation of new investor Rock Springs Capital and current existing investors. This investment will enable the company to initiate Phase 3 clinical trial of drug APR-246 in the treatment of myelodysplastic syndrome. Among drug, phase 3 drugs segment, is expected to witness significant growth in the myelodysplastic syndrome treatment market, owing to increasing pipeline studies, which is expected to get approval in the near future …

EcoR1 Capital

Redmile Group LLC Reduces Holdings in Xencor Inc (NASDAQ:XNCR) | 11/29/2019

Redmile Group LLC lessened its position in shares of Xencor Inc (NASDAQ:XNCR) by 45.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned … after purchasing an additional 213,329 shares in the last quarter. EcoR1 Capital LLC lifted its holdings in Xencor by 13.5% during the 2nd quarter. EcoR1 Capital LLC now owns 2,336,557 shares of the biopharmaceutical company’s …

David Hung and ex-Medivation execs join forces for stealthy cancer startup | FierceBiotech | 10/28/2019

… ECOR1 Capital, Fidelity Management and Research Company, Pavilion Capital, Perceptive Advisors, Redmile Group, Surveyor Capital (a Citadel company) and other institutional investors. Survey Industry Insight Survey: Direct-to-Patient Distribution of Clinical Supplies This industry survey seeks to gain insight on trial sponsors’ perspective on offering a DTP option and their current level of awareness and understanding of any factors that may influence their ability to do so. The first …

McKesson Ventures

Remote Medical Documentation Company Augmedix Closes $19 Million In Funding | 11/6/2019

Remote medical documentation company Augmedix announced that it raised $19 million in Series B funding from Redmile, McKesson, DCM, and Wanxiang Healthcare. Augmedix — a remote medical documentation company — announced recently that it raised $19 million in Series B funding. This round of funding includes investments from Redmile Group, McKesson Ventures, DCM Ventures, Wanxiang Healthcare Investments, and several others. With this round of funding, Augmedix plans to use the funding to …

Health tech funding snapshot—Google joins $50M round in Viz.ai, Augmedix raises $19 million, and more | FierceHealthcare | 11/1/2019

… Redmile Group, McKesson Ventures, DCM Ventures, Wanxiang Healthcare Investments, and others. Augmedix provides clinicians with hardware, smartphones or Google Glass, to stream the clinic visit to a cloud-based platform. Fifteen national health systems, including Sutter Health, CommonSpirit Health, and US Oncology, currently partner with Augmedix. Clinical trial technology: Healthcare technology company SignalPath raised $18 million Series B funding led by existing investors with a total raise of capital to …

DCM Ventures

Remote Medical Documentation Company Augmedix Closes $19 Million In Funding | 11/6/2019

Remote medical documentation company Augmedix announced that it raised $19 million in Series B funding from Redmile, McKesson, DCM, and Wanxiang Healthcare. Augmedix — a remote medical documentation company — announced recently that it raised $19 million in Series B funding. This round of funding includes investments from Redmile Group, McKesson Ventures, DCM Ventures, Wanxiang Healthcare Investments, and several others. With this round of funding, Augmedix plans to use the funding to …

Health tech funding snapshot—Google joins $50M round in Viz.ai, Augmedix raises $19 million, and more | FierceHealthcare | 11/1/2019

… Redmile Group, McKesson Ventures, DCM Ventures, Wanxiang Healthcare Investments, and others. Augmedix provides clinicians with hardware, smartphones or Google Glass, to stream the clinic visit to a cloud-based platform. Fifteen national health systems, including Sutter Health, CommonSpirit Health, and US Oncology, currently partner with Augmedix. Clinical trial technology: Healthcare technology company SignalPath raised $18 million Series B funding led by existing investors with a total raise of capital to …

Jennison Associates

Citadel Advisors LLC Sells 23,438 Shares of Avedro Inc (NASDAQ:AVDR) | 11/1/2019

Jennison Associates LLC bought a new stake in shares of Avedro during the 2nd quarter worth approximately $16,939,000. Vanguard Group Inc. acquired a new position in shares of Avedro during the 2nd quarter worth approximately $5,609,000. BlackRock Inc. acquired a new position in shares of Avedro during the 2nd quarter worth approximately $4,699,000. Redmile Group LLC acquired a new position in Avedro in the 1st quarter valued at $1,534,000. Finally …

Parametric Portfolio Associates LLC Buys New Position in Shockwave Medical Inc (NASDAQ:SWAV) | 10/14/2019

Redmile Group LLC acquired a new stake in shares of Shockwave Medical during the first quarter worth $10,041,000. Jennison Associates LLC acquired a new stake in shares of Shockwave Medical during the second quarter worth $11,323,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Shockwave Medical during the second quarter worth $6,143,000. 47.96% of the stock is owned by hedge funds and other institutional investors. Get Shockwave …

Boxer Capital

Nuvation Bio Raises $275M in Series A Financing | 10/29/2019

By FinSMEs Nuvation Bio, Inc. , a NYC-based stealth biotechnology company developing proprietary therapies focused on oncology, closed a $275 million Series A financing. The round was led, structured and syndicated by Omega Funds and included participation from Aisling Capital, Altitude Life Science Ventures, The Baupost Group, Boxer Capital of the Tavistock Group, EDBI (global Asian-based Investor), ECOR1 Capital, Fidelity Management and Research Company, Pavilion Capital, Perceptive Advisors, Redmile …

Nuvation Bio Pulls In $275M | 10/29/2019

Boxer Capital of the Tavistock Group, EDBI (global Asian-based Investor), ECOR1 Capital, Fidelity Management and Research Company, Pavilion Capital, Perceptive Advisors, Redmile Group, Surveyor Capital (a Citadel Company) and other institutional investors.The Series A financing will enable Nuvation Bio to expand its development activities and advance a number of its oncology programs.Nuvation Bio was founded by industry veteran David Hung, M.D., who previously founded and served as President and …

Aisling Capital

Nuvation Bio Raises $275M in Series A Financing | 10/29/2019

By FinSMEs Nuvation Bio, Inc. , a NYC-based stealth biotechnology company developing proprietary therapies focused on oncology, closed a $275 million Series A financing. The round was led, structured and syndicated by Omega Funds and included participation from Aisling Capital, Altitude Life Science Ventures, The Baupost Group, Boxer Capital of the Tavistock Group, EDBI (global Asian-based Investor), ECOR1 Capital, Fidelity Management and Research Company, Pavilion Capital, Perceptive Advisors, Redmile …

Nuvation Bio Pulls In $275M | 10/29/2019

… Aisling Capital, Altitude Life Science Ventures, The Baupost Group, Boxer Capital of the Tavistock Group, EDBI (global Asian-based Investor), ECOR1 Capital, Fidelity Management and Research Company, Pavilion Capital, Perceptive Advisors, Redmile Group, Surveyor Capital (a Citadel Company) and other institutional investors.The Series A financing will enable Nuvation Bio to expand its development activities and advance a number of its oncology programs.Nuvation Bio was founded by industry veteran David Hung …

Omega Funds

Nuvation Bio Raises $275M in Series A Financing | 10/29/2019

By FinSMEs Nuvation Bio, Inc. , a NYC-based stealth biotechnology company developing proprietary therapies focused on oncology, closed a $275 million Series A financing. The round was led, structured and syndicated by Omega Funds and included participation from Aisling Capital, Altitude Life Science Ventures, The Baupost Group, Boxer Capital of the Tavistock Group, EDBI (global Asian-based Investor), ECOR1 Capital, Fidelity Management and Research Company, Pavilion Capital, Perceptive Advisors, Redmile …

Nuvation Bio Pulls In $275M | 10/29/2019

Omega Funds and included participation from leading biotechnology investors including Aisling Capital, Altitude Life Science Ventures, The Baupost Group, Boxer Capital of the Tavistock Group, EDBI (global Asian-based Investor), ECOR1 Capital, Fidelity Management and Research Company, Pavilion Capital, Perceptive Advisors, Redmile Group, Surveyor Capital (a Citadel Company) and other institutional investors.The Series A financing will enable Nuvation Bio to expand its development activities and advance a number of its …

Altitude Life Science Ventures

Nuvation Bio Raises $275M in Series A Financing | 10/29/2019

By FinSMEs Nuvation Bio, Inc. , a NYC-based stealth biotechnology company developing proprietary therapies focused on oncology, closed a $275 million Series A financing. The round was led, structured and syndicated by Omega Funds and included participation from Aisling Capital, Altitude Life Science Ventures, The Baupost Group, Boxer Capital of the Tavistock Group, EDBI (global Asian-based Investor), ECOR1 Capital, Fidelity Management and Research Company, Pavilion Capital, Perceptive Advisors, Redmile …

Nuvation Bio Pulls In $275M | 10/29/2019

… Altitude Life Science Ventures, The Baupost Group, Boxer Capital of the Tavistock Group, EDBI (global Asian-based Investor), ECOR1 Capital, Fidelity Management and Research Company, Pavilion Capital, Perceptive Advisors, Redmile Group, Surveyor Capital (a Citadel Company) and other institutional investors.The Series A financing will enable Nuvation Bio to expand its development activities and advance a number of its oncology programs.Nuvation Bio was founded by industry veteran David Hung, M.D., who …

Sutter Health

Augmedix Gets $19 million In Funding For Medical Transcribing Platform | 12/1/2019

… nationwide, following the closure of a Series B financing round, where it raised $19 million. The funding included investment from Redmile Group, McKesson Ventures, DCM Ventures, Wanxiang Healthcare Investments, and other unnamed investors. Reducing physician … far, Augmedix has partnered with 15 national health systems, including Sutter Health, CommonSpirit Health, and US Oncology, representing more than 10% of clinicians in the United States. The company says it has more than 1,000 …

Remote Medical Documentation Company Augmedix Closes $19 Million In Funding | 11/6/2019

… documentation company — announced recently that it raised $19 million in Series B funding. This round of funding includes investments from Redmile Group, McKesson Ventures, DCM Ventures, Wanxiang Healthcare Investments, and several others. With this round … to our health system customers.” Fifteen national health systems, including Sutter Health, CommonSpirit Health, and US Oncology — which represent over 10% of clinicians in the US have partnered with Augmedix. “We have strong confidence in …

CommonSpirit Health

Augmedix Gets $19 million In Funding For Medical Transcribing Platform | 12/1/2019

… nationwide, following the closure of a Series B financing round, where it raised $19 million. The funding included investment from Redmile Group, McKesson Ventures, DCM Ventures, Wanxiang Healthcare Investments, and other unnamed investors. Reducing physician … has partnered with 15 national health systems, including Sutter Health, CommonSpirit Health, and US Oncology, representing more than 10% of clinicians in the United States. The company says it has more than 1,000 team members …

Remote Medical Documentation Company Augmedix Closes $19 Million In Funding | 11/6/2019

… documentation company — announced recently that it raised $19 million in Series B funding. This round of funding includes investments from Redmile Group, McKesson Ventures, DCM Ventures, Wanxiang Healthcare Investments, and several others. With this round … health system customers.” Fifteen national health systems, including Sutter Health, CommonSpirit Health, and US Oncology — which represent over 10% of clinicians in the US have partnered with Augmedix. “We have strong confidence in the Augmedix …

HCA

Should You Buy HCA Healthcare Inc (HCA)? | Yahoo News | 12/1/2019

Should You Buy HCA Healthcare Inc (HCA)? Abigail Fisher Reblog Is HCA Healthcare Inc (NYSE: HCA ) a good place to invest some of your money right now? We can gain invaluable insight to help us … interest jumped, key money managers have been driving this bullishness. Redmile Group , managed by Jeremy Green, established the biggest position in HCA Healthcare Inc (NYSE:HCA). Redmile Group had $28.4 million invested in the company …

After shutdown, telemedicine company Call9’s founder plans a comeback | Modern Healthcare | 7/25/2019

… to providing medical care in nursing homes through videoconferencing software was ahead of its time and moved faster than the healthcare industry itself. “It wasn’t viable in the way that we did it,” Peck said … Medicare. Its $24 million Series B round in 2017 attracted Redmile Group, a San Francisco–based investment firm that had previously focused on biotech companies. ArchCare, which runs the Mary Manning Walsh Nursing Home on …

Beth Israel Deaconess Medical Center

After shutdown, telemedicine company Call9’s founder plans a comeback | Modern Healthcare | 7/25/2019

… screeching halt. A healthy start Call9 was founded in 2015 by Peck, an emergency room physician who had practiced at Beth Israel Deaconess Medical Center in Boston; Celina Tenev, a postdoctoral radiology fellow at Stanford … Medicare. Its $24 million Series B round in 2017 attracted Redmile Group, a San Francisco–based investment firm that had previously focused on biotech companies. ArchCare, which runs the Mary Manning Walsh Nursing Home on …

After shutdown, Call9 founder plans a comeback | Crain’s New York Business | 7/25/2019

… screeching halt. A healthy start Call9 was founded in 2015 by Peck, an emergency room physician who had practiced at Beth Israel Deaconess Medical Center in Boston; Celina Tenev, a postdoctoral radiology fellow at Stanford … Medicare. Its $24 million Series B round in 2017 attracted Redmile Group, a San Francisco–based investment firm that had previously focused on biotech companies. ArchCare, which runs the Mary Manning Walsh Nursing Home on …

LHC Group

Redmile Group LLC Has $240,000 Stake in LHC Group, Inc. (NASDAQ:LHCG) | 7/10/2019

Redmile Group LLC lessened its stake in shares of LHC Group, Inc. (NASDAQ:LHCG) by 48.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,166 shares of the health services provider’s stock after selling 2,034 shares during the quarter. Redmile Group LLC’s holdings in LHC Group were worth $240,000 at the end of the …

Redmile Group LLC Cuts Stock Position in LHC Group, Inc. (NASDAQ:LHCG) | 7/2/2019

Redmile Group LLC Cuts Stock Position in LHC Group, Inc. (NASDAQ:LHCG) Posted by Charles Blunt on Jul 2nd, 2019 Redmile Group LLC reduced its position in LHC Group, Inc. (NASDAQ:LHCG) by 48.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,166 shares of the health services provider’s stock after selling 2,034 shares during the quarter. Redmile Group

Centene Corp

Metropolitan Life Insurance Co NY Has $3.44 Million Position in Centene Corp (NYSE:CNC) | 12/2/2019

Metropolitan Life Insurance Co NY reduced its position in shares of Centene Corp (NYSE:CNC) by 0.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 79,490 shares of the company’s stock after selling 512 … after acquiring an additional 741,637 shares in the last quarter. Redmile Group LLC raised its holdings in Centene by 17.3% in the 3rd quarter. Redmile Group LLC now owns 810,498 shares of the company’s stock …

Redmile Group LLC Purchases 119,628 Shares of Centene Corp (NYSE:CNC) | 11/30/2019

Redmile Group LLC raised its stake in shares of Centene Corp (NYSE:CNC) by 17.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 810,498 shares of the company’s stock after purchasing an additional 119,628 shares during the period. Centene accounts for about 1.2% of Redmile Group LLC’s investment portfolio, making the stock its 27th biggest holding. Redmile Group LLC owned approximately 0.20 …

Cigna

Redmile Group LLC Has $265,000 Position in Cigna Corp (NYSE:CI) | 7/10/2019

Redmile Group LLC Has $265,000 Position in Cigna Corp (NYSE:CI) Posted by Shanna Eddington on Jul 9th, 2019 Tweet Redmile Group LLC cut its stake in Cigna Corp (NYSE:CI) by 99.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,648 shares of the health services provider’s stock after selling 273,962 shares during …

Richard Branson and Chamath Palihapitiya Partner to Take Space Tourism Company Virgin Galactic Public: Term Sheet | Fortune | 7/9/2019

… Redmile Group, Invus, MiraeAsset Financial Group, Platinum Asset Management, Jebsen Capital, Steam Athena Capital, BVCF Management and the Struengmann Family Office. – GNS Healthcare, a Cambridge, Mass.-based precision medicine company, raised $23 million in Series D funding. Cigna Ventures led the round, and was joined by investors including Amgen Ventures, Celgene, Echo Health Ventures, Alexandria Venture Investments, and Gary Loveman. – Unmade , a London-based fashion software company, raised £4.75 million …

David Hung

Nuvation Bio Raises $275M in Series A Financing | 10/29/2019

… Redmile Group, Surveyor Capital (a Citadel Company) and other institutional investors. Joining Founder David Hung, M.D., on Nuvation Bio’s Board of Directors are Michelle Doig, Richard Lim and Otello Stampacchia of Omega Funds, as well as former Medivation directors Tony Vernon and Kim Blickenstaff. The company intends to use the funds to expand its development activities and advance a number of its oncology programs. Founded in 2018 by David Hung

Nuvation Bio Pulls In $275M | 10/29/2019

… Redmile Group, Surveyor Capital (a Citadel Company) and other institutional investors.The Series A financing will enable Nuvation Bio to expand its development activities and advance a number of its oncology programs.Nuvation Bio was founded by industry veteran David Hung, M.D., who previously founded and served as President and Chief Executive Officer of Medivation, Inc., which was subsequently sold to Pfizer, Inc. for $14.3 billion in 2016.”My vision for Nuvation …

Ugur Sahin

European tech startups shining: 10 record-breaking funding rounds of Q3 2019 - Silicon Canals | 10/8/2019

… managed by BlackRock. This investment makes Klarna becomes the largest private Fintech in Europe. Picture credits: BioNTech Founders: Christoph Huber, Ugur Sahin Total Funding: €600 million Valuation: $2.5 billion Founded year: 2008 BioNTech is one … Company with participation from both new and existing investors, including Redmile Group, Invus, MiraeAsset Financial Group, Platinum Asset Management, Jebsen Capital, Steam Athena Capital, BVCF Management and the Struengmann Family Office. Picture credits: CMR Surgical …

IPO Update: BioNTech Proposes U.S. IPO Terms - BioNTech (Pending:BNTX) | Seeking Alpha | 9/30/2019

… checkpoint immunomodulators, as well as targeted cancer antibodies and small-molecule drugs. Management is headed by Co-Founder and CEO Ugur Sahin , who previously served as the head of the Scientific Advisory Board of Ganymed … Management, MiraeAsset Asset Management, Jebsen Capital, Invus, BVCF, Athena Capital, Redmile Group, Sanofi ( SNY ), and MIG among others. Source: Crunchbase Lead Candidate Market According to a 2017 market research report by Grand View Research, the …

Tim Peck

After shutdown, telemedicine company Call9’s founder plans a comeback | Modern Healthcare | 7/25/2019

… it would shut down and lay off its remaining 100 workers after peaking with a staff of about 200. Dr. Tim Peck, Call9’s co-founder and CEO, said the company’s approach to providing medical … Medicare. Its $24 million Series B round in 2017 attracted Redmile Group, a San Francisco–based investment firm that had previously focused on biotech companies. ArchCare, which runs the Mary Manning Walsh Nursing Home on …

After shutdown, Call9 founder plans a comeback | Crain’s New York Business | 7/25/2019

… it would shut down and lay off its remaining 100 workers after peaking with a staff of about 200. Dr. Tim Peck, Call9’s co-founder and CEO, said the company’s approach to providing medical … Medicare. Its $24 million Series B round in 2017 attracted Redmile Group, a San Francisco–based investment firm that had previously focused on biotech companies. ArchCare, which runs the Mary Manning Walsh Nursing Home on …

David Hallal

ElevateBio Announces that AlloVir Joins its Portfolio of Highly Innovative Cell and Gene Therapy Companies | Business Wire | 5/22/2019

… stage clinical development as an allogeneic, off-the-shelf multi-virus specific T-cell therapy targeting six common viral pathogens. David Hallal, AlloVir CEO and co-founder of ElevateBio Ann Leen, Ph.D., Chief Scientific Officer … and Research Company, and joined by Gilead Sciences, F2 Ventures, Redmile Group, Invus, EcoR1 Capital, Samsara BioCapital, and Leerink Partners Co-investment Fund, LLC. This press release features multimedia. View the full release here: https …

ElevateBio launches with $150M Series A – to launch cell and gene therapy companies | MedCity News | 5/13/2019

… round was led by the UBS Oncology Impact Fund, which MPM Capital and F2 Ventures manage, along with EcoR1 Capital, Redmile Group and Samsara BioCapital. The company plans to form partnerships with academic researchers, medical … innovative therapies across a growing number of portfolio companies,” CEO David Hallal said in a statement. Hallal said an important element is the company’s research and development, process development and manufacturing center, dubbed the BaseCamp …

David Hall

ElevateBio Announces that AlloVir Joins its Portfolio of Highly Innovative Cell and Gene Therapy Companies | Business Wire | 5/22/2019

… stage clinical development as an allogeneic, off-the-shelf multi-virus specific T-cell therapy targeting six common viral pathogens. David Hallal, AlloVir CEO and co-founder of ElevateBio Ann Leen, Ph.D., Chief Scientific Officer … and Research Company, and joined by Gilead Sciences, F2 Ventures, Redmile Group, Invus, EcoR1 Capital, Samsara BioCapital, and Leerink Partners Co-investment Fund, LLC. This press release features multimedia. View the full release here: https …

ElevateBio launches with $150M Series A – to launch cell and gene therapy companies | MedCity News | 5/13/2019

… round was led by the UBS Oncology Impact Fund, which MPM Capital and F2 Ventures manage, along with EcoR1 Capital, Redmile Group and Samsara BioCapital. The company plans to form partnerships with academic researchers, medical … innovative therapies across a growing number of portfolio companies,” CEO David Hallal said in a statement. Hallal said an important element is the company’s research and development, process development and manufacturing center, dubbed the BaseCamp …